Veterinary Therapeutic Antibody Development
BioVenic offers comprehensive veterinary therapeutic antibody development services, tailored to species-specific therapeutic antibodies for companion animals and other target species. We enable clients to efficiently translate promising antibody candidates into clinically relevant veterinary therapeutics.
Bridging the Gap in Veterinary Therapeutic Antibodies
This service is designed for animal health companies, veterinary pharmaceutical and biotechnology developers, academic research institutions, and CRO/CDMO partners seeking to develop antibody-based therapeutics for companion animals and other target species. It is particularly suitable for teams working on veterinary oncology, allergic diseases, autoimmune disorders, inflammatory conditions, pain management, infectious diseases, and other animal health applications that require species-specific monoclonal antibodies, bispecific antibodies, nanobodies, or engineered antibody candidates.
During development, these teams often face critical pain points, such as limited access to species-specific antibody platforms, insufficient target-animal disease models, and potential immunogenicity caused by heterologous antibody sources. Furthermore, developers may struggle with maintaining antibody affinity and function after caninization, felinization, or other species-specific engineering. Challenges in target validation, efficacy and safety evaluation, PK/PD assessment, and manufacturing consistency can also slow the translation of promising antibody candidates. BioVenic offers comprehensive, end-to-end development services—from initial discovery to downstream evaluation and scalable manufacturing—to help you overcome these obstacles and accelerate the path toward clinically relevant veterinary biologics.
Target Specificity
Precision screening to identify clinically relevant therapeutic targets.
Species-Oriented
Caninization, felinization, and fully species-specific platforms.
Advanced Formats
Innovating with bispecific antibodies and single-domain nanobodies.
Safety Assessed
Robust in vitro and in vivo PK/PD modeling and immunogenicity testing.
Veterinary Therapeutic Antibody Discovery & Engineering
Antibody discovery is the foundational step that directly impacts the therapeutic efficacy of late-stage veterinary biologicals. BioVenic has established diverse platforms tailored for robust screening, preparation, characterization, and downstream structural engineering to ensure you start with the highest quality candidates.
Fig.1 The veterinary therapeutic antibody development services that BioVenic provided (BioVenic Original).
Target Screening and Antibody Preparation
Our target screening platform provides high-throughput technologies—including CRISPR and siRNA library screening, alongside NGS single-cell sequencing—to assist in identifying highly relevant therapeutic targets associated with specific veterinary diseases.
| Platform | Description |
|---|---|
| Hybridoma Platform | Fusion of mouse B lymphocytes and myeloma cells to generate stable monoclonal antibody cell lines. |
| Single B Cell Platform | Single B-cell sorting to isolate and screen highly specific target-binding cells directly from immunized animals. |
| Phage Display Platform | Insertion of exogenous genes into phages to rapidly screen for high-affinity antibodies without necessarily immunizing animals. |
Antibody Characterization and Engineering
Once candidates are prepared, they undergo rigorous structural and functional characterization, detailing their primary/secondary structures, post-translational modifications, and cellular functional affinities. Should heterologous frameworks pose a threat, our Fc engineering, affinity maturation, and structural modification services enhance half-life and improve the overall therapeutic index.
Explore Veterinary Therapeutic Antibody DiscoverySpecies-Specific Therapeutic Antibody Development
Therapeutic antibodies must inherently match the biology of the target species. Heterologous antibodies may increase the risk of anti-drug antibody responses in target animals, potentially compromising efficacy, exposure, and safety. BioVenic supports caninization, felinization, and species-oriented antibody engineering strategies to help reduce immunogenicity risk while preserving target-binding activity.
Antibody Caninization & Felinization
Utilizing chimeric antibody construction and CDR (Complementarity-Determining Region) grafting, BioVenic expertly transplants the active binding regions of an original heterologous antibody onto the framework of a canine or feline antibody. This process drastically reduces immunogenic potential while maintaining essential target affinity, creating highly biocompatible therapeutics for companion animals.
Fully Canine and Feline Antibody Development
Even well-engineered chimeric formats can retain residual heterologous immunogenicity. To further mitigate this risk, BioVenic develops fully species-specific antibodies through Phage Display libraries derived from native sources, Transgenic Mice engineered with companion animal immune genomes, or Single B Cell isolation directly from the target species.
Advanced Veterinary Therapeutic Antibody Formats
Veterinary Therapeutic Bispecific Antibody Development
Bispecific antibodies consist of two distinct binding domains, capable of targeting two separate antigens or epitopes simultaneously. This dual-targeting capability significantly improves therapeutic precision, redirects cytotoxic effector cells directly to the disease site, and lowers off-target toxicity. BioVenic provides multiple construction strategies, including chemical conjugation, hybrid-hybridoma (quadroma) technology, and genetic engineering (e.g., scFv, diabodies, Fab fragments).
Veterinary Therapeutic Nanobody Development
Single-domain antibody formats, including camelid-derived VHHs and shark-derived VNARs, offer compact structures, high stability, and access to challenging epitopes. They provide superior tissue penetration capabilities and robust performance in harsh physiological environments, serving as excellent candidates for complex veterinary oncology treatments and other demanding applications. Our platform streamlines the immunization, panning, and optimization processes needed for potent therapeutic single-domain antibodies.
Effectiveness & Safety Assessments, Manufacturing, and Therapeutics Targets
Moving a candidate from the lab bench to clinical settings necessitates rigorous validation and controlled manufacturing. BioVenic manages these crucial stages with robust disease modeling, arrayed in vitro and in vivo testing platforms, and adaptable manufacturing capabilities.
Effectiveness and Safety Assessments
We utilize comprehensive in vitro assays (cell-based bioactivity, PK property testing, cytotoxicity screening, immunogenicity cytokine detection) paired with stringent in vivo modeling. Our disease models span oncology (subcutaneous/in situ tumor models), allergic diseases (atopic dermatitis), and autoimmune disorders.
Our in vivo arrays quantify pharmacodynamics (biomarkers, optical imaging), pharmacokinetics (ADA screening, toxicokinetics), and broad-spectrum safety pharmacology.
Veterinary Therapeutic Antibody Manufacturing
BioVenic facilitates laboratory-scale manufacturing customized for candidate evaluation. This encompasses the entire chain from antigen design (proteins, peptides, mRNA, VLP) to expression systems (bacterial, yeast, mammalian cells).
Crucially, we execute rigorous Quality Control including cell identification, pathogenic microorganism detection, impurity analysis (CE-SDS, SEC, LC/MS), and stability testing.
Explore Antibody Manufacturing Services →Targeted therapy offers optimal disease-specific characteristics while mitigating side effects on healthy tissues. We support the development of therapies against common high-value targets spanning multiple indications:
Cancer Targets
BRAF, BTK, CD20, CTLA-4, EGFR, HER2, PD-1, PD-L1, VEGF, CD19, CXCR4, KIT, etc.
Allergic Disease Targets
CCL17, CCR4, IL-4, IL-13, IL-31, IL-33, IL-34, IL-4R, TSLP, etc.
Inflammatory & Pain Targets
EP2, EP4, IL-1, TNFα, NGF, IL-34, BTK.
Published Evidence on Species-Oriented Engineering
The Structural Evolution of Monoclonal Antibody Therapeutics
A recent review on monoclonal antibody therapeutics in small animal medicine illustrates the structural differences among murine, chimeric, humanized, caninized, felinized, and fully species-specific antibodies.
Published reviews have summarized structural differences among murine, chimeric, humanized, caninized, felinized, and fully species-oriented antibody formats, supporting the rationale for host-adapted antibody engineering in veterinary therapeutic development. Through precise caninization, felinization, and fully canine or feline antibody development workflows, researchers can effectively reduce potential immune recognition constraints while maintaining necessary target-binding specificity and therapeutic activity.
BioVenic leverages these very principles, integrating advanced engineering to support the development of highly compatible and safe antibody candidates for diverse companion animal applications.
Fig.2 Composition of antibodies. 1,2
Advantages of Our Veterinary Therapeutic Antibody Services
We accelerate your veterinary biologic breakthroughs with end-to-end support, tailored strictly for target animal species.
One-Stop Shop
We cover the entire veterinary therapeutic antibody development process, from initial target discovery and species-specific antibody construction to rigorous in vitro and in vivo safety assessments.
Advanced Technologies
Beyond standard monoclonal antibodies, our utilization of emerging technologies empowers the development of complex veterinary therapeutic bispecific antibodies and high-penetration nanobodies.
Species-Oriented Strategy
Tailored strictly to the target species, our services leverage extensive experience in structural engineering to minimize heterologous components and suppress immunogenicity in companion animals.
Broad Disease Coverage
Based on established hot veterinary targets, we provide development capabilities addressing a wide spectrum of animal diseases, including oncology, allergy, inflammation, pain, and infectious conditions.
Frequently Asked Questions
References
- Wang, Jianzhong, et al. "Current review of monoclonal antibody therapeutics in small animal medicine." Animals 15.4 (2025): 472. https://doi.org/10.3390/ani15040472
- Distributed under Open Access license CC BY 4.0, without modification.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.